This study is in progress, not accepting new patients
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Pamela Munster
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Pamela Munster
Professor, Medicine. Authored (or co-authored) 129 research publications.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- ID
- NCT02009449
- Phase
- Phase 1
- Study Type
- Interventional
- Last Updated